

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## Evaluation Using Cardiac Insertable Devices And Telephone in Hypertrophic Cardiomyopathy (ELUCIDATE HCM) – rationale and design: a prospective interventional observational trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019541
Article Type:	Protocol
Date Submitted by the Author:	08-Sep-2017
Complete List of Authors:	Magnusson, Peter; Center for Research and Development, Uppsala University/Region Gävleborg; Karolinska Institutet Mörner, Stellan; Umeå University, Department of Public Health and Clinical Medicine
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Adult cardiology < CARDIOLOGY, Cardiomyopathy < CARDIOLOGY, Heart failure < CARDIOLOGY, Pacing & electrophysiology < CARDIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic**  
4 **Cardiomyopathy (ELUCIDATE HCM) – rationale and design: a prospective**  
5 **interventional observational trial**  
6  
7  
8

9  
10 Peter Magnusson<sup>1,2</sup> Stellan Mörner<sup>3</sup>

- 11  
12  
13 5 1. Cardiology Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, SE-171 76,  
14 SWEDEN  
15  
16 2. Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, SE-801 87,  
17 SWEDEN  
18  
19 3. Department of Public Health and Clinical Medicine, Umeå University, Umeå, SE-90187, SWEDEN  
20  
21

22 10

23 **Correspondence to:**

24 Peter Magnusson

25 Cardiology Research Unit, Department of Medicine

26 Karolinska Institutet

27  
28  
29  
30  
31 15 Karolinska University Hospital/Solna

32 SE-171 76 Stockholm, SWEDEN

33 Phone: +46(0)705 089407

34 Fax: +46(0)26 154255

35  
36  
37  
38 E-mail: peter.magnusson@regiongavleborg.se  
39

40 20  
41  
42  
43  
44  
45  
46  
47  
48

49 25  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Hypertrophic cardiomyopathy (HCM) is heterogeneous disease associated with sudden cardiac death (SCD) mainly due to ventricular tachycardia (VT) or fibrillation even though life threatening bradycardia occurs. Risk stratification takes several variables into consideration including non-sustained VT. An implantable cardioverter defibrillator effectively prevents SCD.

Atrial fibrillation (AF) is common among HCM patients and warrants anticoagulation even without conventional risk factors according to European guidelines. Routinely, the evaluation of arrhythmias using a 48 hour ambulatory external monitor takes place every 6 to 24 months if patients don't report palpitations. The remaining time the potential burden arrhythmia is unknown. Therefore, the aim of the present study is to assess NSVT and AF incidence during 18 months by an insertable cardiac monitor (ICM).

**Methods:** Adult patients, aged 18-65 years, with a validated diagnosis of HCM are eligible for the study. The study sample is planned to include 30 patients. A Confirm Rx™ is implanted at the level of the fourth rib on the left side subcutaneously after local anesthesia. The application for monitoring is installed in the patients smartphone and symptoms registered by the patient activation and VT detection programmed as 160bpm during  $\geq 8$  intervals. An AF episode is recorded based on  $\geq 2$  minutes duration. Bradycardia is recorded at  $\leq 40$ bpm or pause  $\geq 3.0$  seconds. The patients are followed during 18 months before explant.

**Ethics:** The study was approved by The Regional Ethical Committee in Umeå (protocol number 2017/13-31) The study protocol, including variables and pre-specified research questions the study was registered at Clinical Trial Registration

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

NCT03259113. Each patient is informed about the study in both oral and written form by a physician and included after written consent.

For peer review only

### Strengths and limitations of this study

- An insertable cardiac monitor (ICM) allows for monitoring of atrial fibrillation, significant bradycardia, and non-sustained ventricular tachycardia during 18 months.
- The study will evaluate true incidence of arrhythmia including symptom registration using a smart-phone.
- The detection of atrial fibrillation warrants anticoagulation but very short episodes lack evidence with regard to clinical management.
- Non-sustained ventricular tachycardia is a marker of sudden cardiac death but the decision to implant a defibrillator should be carefully evaluated using guidelines as an ICM is currently not an indication as a diagnostic tool in this regard.
- The costly and invasive ICM may need to be studied in larger hypertrophic cardiomyopathy cohorts to allow for subgroup analyses and to generalize findings.

**Keywords:** atrial fibrillation, hypertrophic cardiomyopathy, implantable loop recorder, insertable cardiac monitor, non-sustained ventricular tachycardia

## INTRODUCTION

The hypertrophic cardiomyopathy (HCM) phenotype in adults requires at least 15mm thickness of the myocardial wall deemed unexplained by other myocardial diseases and abnormal loading conditions due to hypertension or aortic stenosis.<sup>1</sup> The point prevalence is approximately 1:500 in the general population but more than double if genotypes are also included.<sup>2-4</sup> Patients presents with unspecific symptoms such as dyspnea, chest discomfort, and dizziness. Echocardiogram is the cornerstone in diagnosing HCM but integrated medical information and awareness of differential diagnoses are important to avoid misclassification.<sup>5-7</sup> The severity and pattern of hypertrophy and disease progression varies considerably.<sup>5</sup> Life expectancy in general HCM cohorts seems to be acceptable but end-stage heart failure, cardiac embolization stroke, and devastating arrhythmias remain a challenge in order to improve prognosis.<sup>8-12</sup>

Sudden cardiac death (SCD) can be prevented by an implantable defibrillator cardioverter (ICD). In a recent review of HCM patients with ICDs, 4.8% experienced appropriate therapy annually due to ventricular tachycardia (VT) or fibrillation and antitachycardia pacing or cardioversion rarely fails.<sup>13</sup> The decision to implant an ICD as primary prevention of SCD is based evaluation of riskmarkers according to guidelines.<sup>14,15</sup> In both 2011 and 2014 guidelines, non-sustained VT (NSVT) is part of risk stratification based on evidence from several studies.<sup>16-19</sup> It is more common at higher age and correlates with increased left ventricular wall thickness.<sup>16,20</sup> NSVT may be revealed during an ambulatory ECG or at telemetry in the ward or at exercise test. HCM guidelines advocate follow-up including 48 hour ambulatory ECG whenever onset of palpitations or otherwise every 12-24 months but 6-12 months if the patient is in sinus rhythm and has enlarged left atrial diameter which predisposes

1  
2  
3 for AF and SCD.<sup>15</sup> This implies that during the remaining time the presence of  
4  
5 NSVT/AF is unknown.  
6  
7

8 In HCM, AF is known to worsen symptoms due to vulnerability to increased heart rate  
9  
10 and lack of atrial filling. Furthermore, atrial fibrillation (AF) associated with ischemic  
11  
12 stroke or systemic embolization is a major cause of death in HCM, which warrants  
13  
14 attention to detection methods with increased sensitivity.<sup>11</sup> In fact, according to  
15  
16 current HCM-guidelines, a history of AF, even without any CHA2DS2-VASc risk  
17  
18 factor is an indication of anticoagulation.<sup>15</sup>  
19  
20

21  
22 The insertable cardiac monitor (ICM) Confirm Rx™ (Abbott/St. Jude Medical, St.  
23  
24 Paul, MN, USA) provides long-term monitoring of atrial and ventricular arrhythmias in  
25  
26 addition to bradycardia.<sup>21</sup> This device could potentially reveal the true incidence of  
27  
28 arrhythmia in HCM patients which is the rationale of the present study: Evaluation  
29  
30 Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy  
31  
32 (ELUCIDATE HCM).  
33  
34

## 35 36 15 **OBJECTIVES**

37  
38 Primary objective is to assess the incidence of NSVT during 18 months follow-up  
39  
40 using an ICM.  
41  
42

43  
44 Secondary objective is to assesses the incidence of AF during 18 months follow-up  
45  
46 using an ICM.  
47  
48

## 49 20 **METHODS**

### 50 51 *Setting and selection*

52  
53  
54 Adult patients with a confirmed of HCM, will be recruited from the catchment area of  
55  
56 Region Gävleborg and Umeå University hospital (tertiary center) in northern Sweden.  
57  
58  
59  
60



1  
2  
3 Eligible patients are identified from hospital data-bases (diagnostic codes I42.1 or  
4 I42.2) and validated using medical records. The recruitment started in August 2017.  
5  
6

### 7 8 *Inclusion and exclusion* 9

10 Patients, aged 18-65 years, with a confirmed diagnosis of HCM are eligible for the  
11  
12 study. Exclusion criteria as follows: aortic stenosis (moderate, severe), hypertrophy  
13  
14 assoacied with metabolic disease (e.g. Fabry-Andersen) and syndromes (e.g.  
15  
16 Noonan syndrome), systolic heart failure with ejection fraction  $\leq 55\%$ , pacemaker,  
17  
18 implantable defibrillator, myocardial infarction, percutenous coronary intervention,  
19  
20 coronary by-pass grafting, pulmonaru vein isolation, Maze surgery, VT ablation,  
21  
22 ectopica atrial tachycardia ablation, renal clearance  $\leq 40$ , malignancy or other  
23  
24  
25  
26 comorbidity with  $\leq 5$  years life expectancy, pregnancy (or planned  $\leq 18$  months), drug  
27  
28 addition, severe psychiatric disease, not able to participate in 18 months follow-up, 5-  
29  
30 year risk of sudden cardiac death  $\geq 6\%$  according to the risk calculator.<sup>19</sup>  
31  
32

### 33 34 *Implantation and monitor set-up* 35

36  
37 15 The implantation procedure is performed in local infiltrative anesthesia (carbocaine  
38  
39 with epinephrine) using the standard operation kit for Confirm Rx™ via a 5mm  
40  
41 incision at the level of the fourth rib on the left side subcutaneously. The application for  
42  
43 monitoring is installed in the patients own smart-phone or a one that will be lent  
44  
45 during the study period. The connection to the home-monitoring site Merlin™ is  
46  
47  
48 20 administrated and the patient is instructed how to use application and report potential  
49  
50 symptoms according to guidelines.<sup>22</sup> Post-procedure, paracetamol (acetaminophen)  
51  
52 is recommended to control pain.  
53  
54

### 55 56 *Programming* 57 58 59 60

1  
2  
3 VT detection is programmed as 160bpm during  $\geq 8$  intervals with high EGM priority  
4 and discriminator sudden onset activated (onset delta 18%) a bigemini qualifier off.

5 An AF episode is recorded based on  $\geq 2$  minutes duration, AF-burden  $\geq 6$  hours a day,

6 or ventricular rate during AF 100bpm for 6 hours daily. Bradycardia is recorded at

7  
8  
9  
10  
11  
12 5  $\leq 40$ bpm or pause  $\geq 3.0$  seconds. Patient-activated symptom episodes have high EGM

13 priority with 6 minutes symptom pre-trigger duration and 1 minute symptom post-

14 trigger duration and the first 8 EGMs are stored. Maximal ventricular sensitivity is

15 typically 0.15mV but adjusted if R-waves are low. Threshold start is 75% and sense

16 refractory period 250ms and decay delay 60ms.  
17  
18  
19  
20  
21

## 22 23 10 *Power analysis*

24  
25 A power analysis is based on previous research findings and estimation of outcome

26 with certain relevance of hypothesis testing. This is the first study on incidence of

27  
28 NSVT and AF in HCM using continuous monitoring for a period of 18 months. Thus

29  
30 the diagnostic yield is unknown. A power formal analysis is have not been conducted

31  
32  
33  
34  
35 15 and estimation of sample size is based on clinical judgement and available

36 resources.  
37  
38

## 39 40 *Statistics*

41  
42 Numeric data will be presented as frequencies, percentages, means, and percentiles.

43  
44 Continuous variables are summarized as means, standard deviations, and

45  
46  
47 20 percentiles, and compared using t-tests. The chi-squared test is used for categorical

48 variables. Kaplan-Meier estimates is used to describe time to event analysis (time

49 from implant to AF and NSVT respectively and cumulative incidence at 6,12, and 18

50  
51  
52  
53  
54  
55 months will be reported.  
56  
57  
58  
59  
60

1  
2  
3 A two-sided  $p$ -value of  $<0.05$  is considered statistically significant. The database will  
4  
5 be stored in Excel 2010 (Microsoft Corporation, Redmond, WA) and imported into  
6  
7 SPSS version 22 (IBM, Armonk, NY) for statistical analyses.  
8  
9

### 10 *Variables*

11  
12  
13 5 Patient characteristics at enrollment as follows: age, family history of SCD,  
14  
15 unexplained syncope, known HCM associated mutation, weight, length, NSVT at 48  
16  
17 ambulatory ECG. Echocardiography parameters such as maximal wall thickness, left  
18  
19 ventricular outflow tract gradient, left atrial size will be recorded.  
20  
21

### 22 *Ethics and Registration*

23  
24  
25 10 The Regional Ethical Committee in Umeå approved the study the 7<sup>th</sup> of February  
26  
27 2017 (protocol number 2017/13-31), which is conducted in accordance with the  
28  
29 Declaration of Helsinki.<sup>23</sup> The study protocol, including variables and pre-specified  
30  
31 research questions the study was registered at Clinical Trial Registration  
32  
33 NCT03259113 and approved 24<sup>th</sup> of August 2017. Documentaton of research data  
34  
35  
36 15 and management of study follow Guideline for Good Clinical Practice.<sup>24</sup> Each patient  
37  
38 is informed about the study in both oral and written form by a physician and included  
39  
40 after written consent.  
41  
42

## 43 **DISCUSSION**

44  
45  
46  
47 This is the first study on arrhythmia detection in HCM using an ICM. These devices  
48  
49 20 offer the superior advantage of prolonged monitoring in comparison to external loop-  
50  
51 recorders. ICM is currently used in certain cases of HCM such as syncope evaluation  
52  
53 but not in routine evaluation. The application of ICM in the specific group of HCM has  
54  
55 been proposed already in statements of research priorities.<sup>25</sup>  
56  
57  
58  
59  
60

1  
2  
3 The newly launched Confirm Rx™ uses a smart-phone application that is used  
4  
5 instead of a standard home-monitor and provide the possibility of remote monitoring  
6  
7 and symptom registration.  
8  
9

10  
11 Until now, 48 hour ambulatory monitoring is used, but often telemetry in hospital  
12  
13 wards detect arrhythmias in HCM. That means that these modes of monitoring may  
14  
15 coincidentally detect AF and VT but with increased likelihood in patients with higher  
16  
17 incidence of arrhythmias. It is unclear if a higher incidence of arrhythmia reflects a  
18  
19 higher risk of and our study has a small sample size and no long-term follow-up of  
20  
21 outcomes of SCD. Even though this study will elucidate the true arrhythmia  
22  
23  
24 10 incidence, the clinical interpretation will remain partly unsolved. In addition, ICMs are  
25  
26 costly devices and health economy analyses will be needed before potential use in  
27  
28 broader HCM groups.  
29

30  
31 AF detection is important in HCM because of the increased of embolic stroke.<sup>11</sup> AF  
32  
33 detection by ICM is superior compared to standard evaluation of monitoring in  
34  
35 15 cryptogenic stroke.<sup>26</sup> However, it should be remembered that clinical management of  
36  
37 patients whose AF was detected at pacemaker interrogation is controversial, but  
38  
39 there is compelling evidence when duration is at least six minutes.<sup>27</sup> Patients with  
40  
41 silent AF, i.e. asymptomatic still carry a considerable risk and should be managed the  
42  
43 conventional way with regard to anticoagulation.<sup>27</sup> Even though the definition of AF is  
44  
45  
46 20 an atrial electrical activity of  $\geq 300$  per minutes during  $\geq 30$ s, devices such as  
47  
48 pacemaker register atrial high rate and the benefit of apixaban is currently studied.  
49  
50 The correlation to symptoms is possible in our study and future smartphone-based  
51  
52 ICM usage is promising.<sup>28</sup>  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Safety aspects during the study imply referral to the patients physician for  
4  
5 anticoagulation if AF is detected, sustained VT/ ventricular fibrillation for decision-  
6  
7 making with regard to an ICD and if a significant bradycardia occur that implies a  
8  
9 pacemaker indication.  
10

11  
12 5 Future research of larger series of HCM patients using ICM:s with a sample size and  
13  
14 subgroups like patients who have undergone myectomy or alcohol septal ablation are  
15  
16 welcomed. Interestingly, the ICM size has become reduced over time, and  
17  
18 implantation techniques have become simpler, which allows for more favourable  
19  
20 cost-benefit as implantation outside the electrophysiological laboratory is possible.  
21  
22

23  
24 10 Still, this is the first study on arrhythmia burden and symptoms in consecutive  
25  
26 unselected HCM patients using an ICM connected to a smart-phone for monitoring  
27  
28 and symptom elucidation.  
29

### 30 31 **Acknowledgements** 32

33  
34 The authors acknowledge Anders Edström, Abbott, who provided support and  
35  
36 guidance.  
37  
38 15

### 39 40 **Author contributions** 41

42 PM: idea, design, project management, and writing the manuscript. SM: critical  
43  
44 revision of the manuscript and project management.  
45  
46

### 47 48 **Funding** 49

50 20 Region Gävleborg funded this research project and Abbott/St Jude Medical provided  
51  
52 funding for the Confirm Rx™ (grant number 84540).  
53  
54

### 55 56 **Competing interests** 57 58 59 60

1  
2  
3 The authors received a research grant from Abbott /St Jude Medical (see funding  
4 section)  
5  
6

### 7 8 **Ethics approval**

9  
10 The study was approved by the Regional Ethical committee in Umeå (Dnr 2017/13-  
11 5 31).  
12  
13

### 14 15 **REFERENCES**

- 16  
17  
18 1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a  
19 position statement from the European Society Of Cardiology Working Group on  
20 Myocardial and Pericardial Diseases. *Eur Heart J* 2008; 29: 270-6.  
21  
22  
23  
24  
25  
26 10 2. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy  
27 in a general population of young adults. Echocardiographic analysis of 4111 subjects  
28 in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.  
29  
30  
31  
32  
33  
34  
35  
36 3. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic  
37  
38 15 cardiomyopathy in China: a population-based echocardiographic analysis of 8080  
39 adults. *Am J Med* 2004;116:14-18.  
40  
41  
42  
43 4. Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of  
44 hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2015;65:1249-54.  
45  
46  
47  
48 5. Klues HG, Schiffrers A, Maron BJ. Phenotypic spectrum and patterns of left  
49  
50 20 ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations  
51 and significance as assessed by two-dimensional echocardiography in 600 patients.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61

- 1  
2  
3 6. Losi MA, Nistri S, Galderisi M, et al. Echocardiography in patients with  
4 hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis  
5 and pathophysiological assessment. *Cardiovasc Ultrasound* 2010;8:7.  
6  
7  
8  
9  
10 7. Magnusson P, Palm A, Branden E, et al. Misclassification of hypertrophic  
11 cardiomyopathy: validation of diagnostic codes. *Clin Epidemiology* 2017;9: 403-10.  
12 5  
13  
14  
15 8. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic Cardiomyopathy in Adulthood  
16 Associated With Low Cardiovascular Mortality With Contemporary Management  
17 Strategies. *J Am Coll Cardiol* 2015;65:1915-28.  
18  
19  
20  
21  
22 9. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic  
23 cardiomyopathy-related death: revisited in a large non-referral-based patient  
24 10 population. *Circulation* 2000;102:858-64.  
25  
26  
27  
28  
29  
30 10. Pasqualucci D, Fornaro A, Castelli G, et al. Clinical Spectrum, Therapeutic  
31 Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy.  
32 *Circ Heart Fail* 2015;8:1014-21.  
33  
34  
35  
36  
37 11. Guttman OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and  
38 15 thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.  
39 *Heart* 2014;100:465-72.  
40  
41  
42  
43  
44 12. Magnusson P, Gadler F, Liv P, et al. Causes of death and mortality in  
45 hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden. *J*  
46 *Cardiovasc Med (Hagerstown)* 2016;17:478-84.  
47 20  
48  
49  
50  
51  
52 13. Wang N, Xie A, Tjahjono R, et al. Implantable cardioverter defibrillator therapy in  
53 hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of  
54 outcomes and complications. *Annals of cardiothoracic surgery* 2017;6;298-306.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 14. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the  
4 diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a  
5 report of the American College of Cardiology Foundation/American Heart Association  
6 Task Force on Practice Guidelines. *Circulation* 2011;124:2761-96.  
7  
8  
9  
10  
11  
12 5 15. Elliott PM, Anastakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis  
13 and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis  
14 and Management of Hypertrophic Cardiomyopathy of the European Society of  
15 Cardiology (ESC). *Eur Heart J* 2014;35:2733-79.  
16  
17  
18  
19  
20  
21  
22 16. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia  
23 in hypertrophic cardiomyopathy: an independent marker of sudden death risk in  
24 10 young patients. *J Am Coll Cardiol* 2003;42:873-9.  
25  
26  
27  
28  
29  
30 17. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic  
31 significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic  
32 cardiomyopathy. *J Am Coll Cardiol*. 2005;45:697-704.  
33  
34  
35  
36  
37 15 18. Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. Outcome and complications  
38 after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy:  
39 systematic review and meta-analysis. *Circ Heart Fail* 2012;5:552-9.  
40  
41  
42  
43  
44 19. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for  
45 sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). *Eur Heart J*  
46 2014;35:2010-20.  
47  
48 20  
49 20. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial  
50 fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;56:867-74.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 21. Nölker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac  
4 Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. *J Cardiovasc*  
5 *Electrophysiol* 2016;12:1403-10.  
6  
7  
8  
9  
10 22. Dubner S, Auricchio A, Steinberg J. et al. (2012). ISHNE/EHRA expert  
11  
12 5 consensus on remote monitoring of cardiovascular implantable electronic devices  
13 (CIEDs). *Europace* 2012;14:278–93.  
14  
15  
16  
17 23. (2002) World Medical Association Declaration of Helsinki: ethical principles for  
18 medical research involving human subjects. *J Postgrad Med* 2002;48:206-8.  
19  
20  
21  
22 24. European Medicines Agency (2002) ICH harmonised tripartite guideline E6. In:  
23  
24 10 EMA, eds. Note for Guidance on Good Clinical Practice (PMP/ICH/135/95).  
25  
26  
27  
28 25. Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic  
29 cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood  
30 Institute. *Circulation* 2010;122:1130-3.  
31  
32  
33  
34  
35 26. Sanna T, Diener HC, Passman RS, et al; CRYSTAL AF Investigators.  
36  
37 15 Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014;370:2478-86.  
38  
39  
40 27. Healey JS, Connolly SJ, Gold MR, et al.; ASSERT Investigators. Subclinical atrial  
41 fibrillation and the risk of stroke. *N Engl J Med* 2012;366:120-9.  
42  
43  
44  
45 28. Mittal S. Smartphone-Based Electrocardiographic and Cardiac Implantable  
46 Electronic Device Monitoring. *Cardiol Rev* 2017;25:12-16.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Evaluation Using Cardiac Insertable Devices And Telephone in Hypertrophic Cardiomyopathy (ELUCIDATE HCM) – rationale and design: a prospective observational study on incidence of arrhythmias

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019541.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Oct-2017
Complete List of Authors:	Magnusson, Peter; Center for Research and Development, Uppsala University/Region Gävleborg; Karolinska Institutet Mörner, Stellan; Umeå University, Department of Public Health and Clinical Medicine
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Adult cardiology < CARDIOLOGY, Cardiomyopathy < CARDIOLOGY, Heart failure < CARDIOLOGY, Pacing & electrophysiology < CARDIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic**  
4 **Cardiomyopathy (ELUCIDATE HCM) – rationale and design: a prospective**  
5 **observational study on incidence of arrhythmias.**  
6  
7  
8

9  
10 Peter Magnusson<sup>1,2</sup> Stellan Mörner<sup>3</sup>

- 11  
12  
13 5 1. Cardiology Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, SE-171 76,  
14 SWEDEN  
15  
16 2. Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, SE-801 87,  
17 SWEDEN  
18  
19 3. Department of Public Health and Clinical Medicine and Heart Center, Umeå University, Umeå, SE-  
20  
21 10 90187, SWEDEN  
22  
23  
24

25 **Correspondence to:**

26 Peter Magnusson

27 Cardiology Research Unit, Department of Medicine

28  
29  
30  
31 15 Karolinska Institutet

32 Karolinska University Hospital/Solna

33 SE-171 76 Stockholm, SWEDEN

34 Phone: +46(0)705 089407

35 Fax: +46(0)26 154255

36  
37  
38  
39  
40 20 E-mail: peter.magnusson@regiongavleborg.se  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 25

## ABSTRACT

**Introduction:** Hypertrophic cardiomyopathy (HCM) is heterogeneous disease associated with sudden cardiac death (SCD) mainly due to ventricular tachycardia (VT) or fibrillation even though life threatening bradycardia occurs. Risk stratification takes several variables into consideration including non-sustained VT. An implantable cardioverter defibrillator effectively prevents SCD.

Atrial fibrillation (AF) is common among HCM patients and warrants anticoagulation even without conventional risk factors according to European guidelines. Routinely, the evaluation of arrhythmias using a 48 hour ambulatory external monitor takes place every 6 to 24 months if patients don't report palpitations. The remaining time the potential burden arrhythmia is unknown. Therefore, the aim of the present study is to assess NSVT and AF incidence during 18 months by an insertable cardiac monitor (ICM).

**Methods:** Adult patients, aged 18-65 years, with a validated diagnosis of HCM are eligible for the study. The study sample is planned to include 30 patients. A Confirm Rx™ is implanted at the level of the fourth rib on the left side subcutaneously after local anesthesia. The application for monitoring is installed in the patients smartphone and symptoms registered by the patient activation and VT detection programmed as 160bpm during  $\geq 8$  intervals. An AF episode is recorded based on  $\geq 2$  minutes duration. Bradycardia is recorded at  $\leq 40$ bpm or pause  $\geq 3.0$  seconds. The patients are followed during 18 months before explant.

**Ethics and dissemination:** The study was approved by The Regional Ethical Committee in Umeå (protocol number 2017/13-31) The study protocol, including

1  
2  
3 variables and pre-specified research questions the study was registered at Clinical  
4  
5 Trial Registration NCT03259113. Each patient is informed about the study in both  
6  
7 oral and written form by a physician and included after written consent.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- An insertable cardiac monitor (ICM) allows for monitoring of atrial fibrillation, significant bradycardia, and non-sustained ventricular tachycardia during 18 months.
- The study will evaluate true incidence of arrhythmia including symptom registration using a smart-phone.
- The detection of atrial fibrillation warrants anticoagulation but very short episodes (<5 minutes) lack evidence with regard to clinical management.
- Non-sustained ventricular tachycardia is a marker of sudden cardiac death but the decision to implant a defibrillator should be carefully evaluated using guidelines as an ICM is currently not an indication as a diagnostic tool in this regard.
- The costly and invasive ICM may need to be studied in larger hypertrophic cardiomyopathy cohorts to allow for subgroup analyses and to generalize findings.

**Keywords:** atrial fibrillation, hypertrophic cardiomyopathy, implantable loop recorder, insertable cardiac monitor, non-sustained ventricular tachycardia

## INTRODUCTION

The hypertrophic cardiomyopathy (HCM) phenotype in adults requires at least 15mm thickness of the myocardial wall deemed unexplained by other myocardial diseases and abnormal loading conditions due to hypertension or aortic stenosis.<sup>1</sup> The point prevalence is approximately 1:500 in the general population but more than double if genotypes are also included.<sup>2-4</sup> Patients present with unspecific symptoms such as dyspnea, chest discomfort, palpitations, and dizziness. Echocardiogram is the cornerstone in diagnosing HCM but integrated medical information and awareness of differential diagnoses are important to avoid misclassification.<sup>5-7</sup> The severity and pattern of hypertrophy and disease progression varies considerably.<sup>5</sup> Life expectancy in general HCM cohorts seems to be acceptable but end-stage heart failure, cardiac embolization stroke, and devastating arrhythmias remain a challenge in order to improve prognosis.<sup>8-12</sup>

Sudden cardiac death (SCD) can be prevented by an implantable cardioverter-defibrillator (ICD). In a recent review of HCM patients with ICDs, 4.8% experienced appropriate therapy annually due to ventricular tachycardia (VT) or fibrillation and antitachycardia pacing or cardioversion rarely fails in terminating the arrhythmia.<sup>13</sup> The decision to implant an ICD as primary prevention of SCD is based on evaluation of riskmarkers according to guidelines.<sup>14,15</sup> In both 2011 and 2014 guidelines, non-sustained VT (NSVT) is part of risk stratification based on evidence from several studies.<sup>16-19</sup> It is more common at an older age and correlates with increased left ventricular wall thickness.<sup>16,20</sup> NSVT may be revealed during an ambulatory ECG, telemetry in the ward or during exercise test. HCM guidelines advocate follow-up including 48 hour ambulatory ECG whenever onset of palpitations or otherwise every 12-24 months but 6-12 months if the patient is in sinus rhythm and has enlarged left

atrial diameter which predisposes for atrial fibrillation (AF) and SCD.<sup>15</sup> This implies that during the remaining time the presence of NSVT/AF is unknown.

In HCM, AF is known to worsen symptoms due to vulnerability to increased heart rate and lack of atrial filling. Furthermore, AF associated with ischemic stroke or systemic embolization is a major cause of death in HCM, which warrants attention to detection methods with increased sensitivity.<sup>11</sup> In fact, according to current HCM-guidelines, a history of AF, even without any CHA2DS2-VASc risk factor is an indication of anticoagulation.<sup>15</sup>

The insertable cardiac monitor (ICM) Confirm Rx™ (Abbott/St. Jude Medical, St. Paul, MN, USA) provides long-term monitoring of atrial and ventricular arrhythmias in addition to bradycardia.<sup>21</sup> This device could potentially reveal the true incidence of arrhythmia in HCM patients which is the rationale of the present study: Evaluation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM).

## OBJECTIVES

Primary objective is to assess the incidence of NSVT during 18 months follow-up using an ICM.

Secondary objective is to assesses the incidence of AF during 18 months follow-up using an ICM.

## METHODS

### *Setting and selection*

Adult patients with a confirmed diagnosis of HCM, will be recruited from the catchment area of Region Gävleborg and Umeå University hospital (tertiary center) in



1  
2  
3 northern Sweden. Eligible patients are identified from hospital data-bases (diagnostic  
4 codes I42.1 or I42.2) and validated using medical records. The recruitment started in  
5 August 2017.  
6  
7  
8

9  
10 *Inclusion and exclusion*  
11

12  
13 5 Patients, aged 18-65 years, with a confirmed diagnosis of HCM are eligible for the  
14 study. Exclusion criteria as follows: aortic stenosis (moderate, severe), hypertrophy  
15 associated with metabolic disease (e.g. Fabry-Andersen) and syndromes (e.g.  
16 Noonan syndrome), systolic heart failure with ejection fraction  $\leq 55\%$ , pacemaker,  
17 implantable defibrillator, myocardial infarction, percutaneous coronary intervention,  
18 coronary by-pass grafting, pulmonary vein isolation, Maze surgery, VT ablation,  
19 ectopic atrial tachycardia ablation, renal clearance  $\leq 40$  mL/min (Cockcroft-Gault  
20 Equation), malignancy or other comorbidity with  $\leq 5$  years life expectancy, pregnancy  
21 (or planned  $\leq 18$  months), drug addition, severe psychiatric disease, not able to  
22 participate in 18 months follow-up, 5-year risk of sudden cardiac death  $\geq 6\%$   
23 according to the risk calculator.<sup>19</sup> Myectomy or alcohol septal ablation is not an  
24 exclusion criterion.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

40 *Implantation and monitor set-up*  
41

42  
43 The implantation procedure is performed in local infiltrative anesthesia (carbocaine  
44 with epinephrine) using the standard operation kit for Confirm Rx™ via a 5mm  
45 incision at the level of the fourth rib on the left side subcutaneously. The application for  
46 monitoring is installed on the patients own smart-phone or a one that will be lent  
47 during the study period. The connection to the home-monitoring site Merlin™ is  
48 administrated and the patient is instructed how to use application and report potential  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 symptoms according to guidelines.<sup>22</sup> Post-procedure, paracetamol (acetaminophen)  
4  
5 is recommended to control pain.  
6  
7

### 8 *Programming*

9  
10 VT detection is programmed as 160bpm during  $\geq 8$  intervals with high electrogram  
11  
12 (EGM) priority and discriminator sudden onset activated (onset delta 18%) a  
13 5 (EGM) priority and discriminator sudden onset activated (onset delta 18%) a  
14  
15 bigemini qualifier off. An AF episode is recorded based on  $\geq 2$  minutes duration (the  
16  
17 shortest programmable duration), AF-burden  $\geq 6$  hours a day, or ventricular rate  
18  
19 during AF 100bpm for 6 hours daily. Bradycardia is recorded at  $\leq 40$ bpm or pause  
20  
21  $\geq 3.0$  seconds. Patient-activated symptom episodes have high EGM priority with 6  
22  
23 10 minutes symptom pre-trigger duration and 1 minute symptom post-trigger duration  
24  
25 and the first 8 EGMs are stored. Maximal ventricular sensitivity is typically 0.15mV  
26  
27 but adjusted if R-waves are low. Threshold start is 75% and sense refractory period  
28  
29 250ms and decay delay 60ms.  
30  
31  
32

### 33 *Follow-up*

34  
35  
36 15 Patients are encouraged to report symptoms by using the smart phone application. In  
37  
38 addition, every third month there is an automatic interrogation of the device and  
39  
40 transfer to the home-monitoring site Merlin,<sup>TM</sup> which is reviewed every second day  
41  
42 except for weekends. False detection of arrhythmia by the device is expected to be  
43  
44 frequent based on experience. Therefore all episodes are scrutinized as part of work-  
45  
46 20 process. At 18 months, the device is explanted. Patients are scheduled for follow-up  
47  
48 every third months but detection of arrhythmia warrants contact with the patient as  
49  
50 part of clinical management.  
51  
52  
53

### 54 *Power analysis*

1  
2  
3 A power analysis is based on previous research findings and estimation of outcome  
4 with certain relevance of hypothesis testing. This is the first study on incidence of  
5 NSVT and AF in HCM using continuous monitoring for a period of 18 months. Thus  
6 the diagnostic yield is unknown. A formal power analysis is have not been conducted  
7  
8  
9  
10  
11  
12 5 and estimation of sample size is based on clinical judgement and available  
13  
14 resources.

### 15 16 17 *Statistics*

18  
19  
20 Numeric data will be presented as frequencies, percentages, means, and percentiles.  
21  
22 Continuous variables are summarized as means, standard deviations, and  
23  
24 10 percentiles, and compared using t-tests. The chi-squared test is used for categorical  
25  
26 variables. Kaplan-Meier estimates is used to describe time to event analysis (time  
27  
28 from implant to AF and NSVT respectively and cumulative incidence at 6,12, and 18  
29  
30 months will be reported.  
31

32  
33  
34 A two-sided  $p$ -value of  $<0.05$  is considered statistically significant. The database will  
35  
36 15 be stored in Excel 2010 (Microsoft Corporation, Redmond, WA) and imported into  
37  
38 SPSS version 22 (IBM, Armonk, NY) for statistical analyses.  
39

### 40 41 *Variables*

42  
43  
44 Patient characteristics at enrollment as follows: age, family history of SCD,  
45  
46 unexplained syncope, known HCM associated mutation, weight, length, NSVT at 48  
47  
48 20 hours ECG. Echocardiography parameters such as maximal wall thickness, left  
49  
50 ventricular outflow tract gradient, left atrial size will be recorded.  
51

### 52 53 *Ethics and dissemination*

1  
2  
3 The Regional Ethical Committee in Umeå approved the study the 7<sup>th</sup> of February  
4  
5 2017 (protocol number 2017/13-31), which is conducted in accordance with the  
6  
7 Declaration of Helsinki.<sup>23</sup> The study protocol, including variables and pre-specified  
8  
9 research questions the study was registered at Clinical Trial Registration  
10  
11 NCT03259113 and approved 24<sup>th</sup> of August 2017. Documentaton of research data  
12  
13 and management of study follow Guideline for Good Clinical Practice.<sup>24</sup> Each patient  
14  
15 is informed about the study in both oral and written form by a physician and included  
16  
17 after written consent. After the follow-up period is completed, the database will be  
18  
19 close and followed by statistical work, interpretation of results, and dissemination to a  
20  
21 scientific journal.  
22  
23  
24  
25

## 26 **DISCUSSION**

27  
28 This is the first study on arrhythmia detection in HCM using an ICM. These devices  
29  
30 offer the superior advantage of prolonged monitoring in comparison to external loop-  
31  
32 recorders. ICM is currently used in certain cases of HCM such as syncope evaluation  
33  
34 or possibly in patients with frequent palpitations, but not in routine evaluation. The  
35  
36 application of ICM in the specific group of HCM has been proposed already in  
37  
38 statements of research priorities.<sup>25</sup>  
39  
40  
41

42 The newly launched Confirm Rx<sup>TM</sup> uses a smart-phone application that is used  
43  
44 instead of a standard home-monitor and provide the possibility of remote monitoring  
45  
46 and symptom registration.  
47  
48  
49

50 Until now, 48 hour ambulatory monitoring is used, but often telemetry in hospital  
51  
52 wards detect arrhythmias in HCM. That means that these modes of monitoring may  
53  
54 coincidentally detect AF and VT but with increased likelihood in patients with higher  
55  
56 incidence of arrhythmias. It is unclear if a higher incidence of arrhythmia reflects a  
57  
58  
59  
60

1  
2  
3 higher risk of SCD/stroke and our study has a small sample size and no long-term  
4  
5 follow-up of outcomes of SCD. Even though this study will elucidate the true  
6  
7 arrhythmia incidence, the clinical interpretation will remain partly unsolved. In  
8  
9 addition, ICMs are costly devices and health economy analyses will be needed  
10  
11  
12 5 before potential use in broader HCM groups.

13  
14 Detection of AF is important in HCM because of the increased of embolic stroke.<sup>11</sup>  
15  
16 AF detection by ICM is superior compared to standard evaluation of monitoring in  
17  
18 cryptogenic stroke.<sup>26</sup> However, it should be remembered that clinical management of  
19  
20 patients whose AF was detected at pacemaker interrogation is controversial, but  
21  
22  
23 10 there is compelling evidence when duration is at least six minutes.<sup>27</sup> Patients with  
24  
25 silent AF, i.e. asymptomatic still carry a considerable risk and should be managed the  
26  
27 conventional way with regard to anticoagulation.<sup>27</sup> Even though the definition of AF is  
28  
29 an atrial electrical activity of  $\geq 300$  beats per minutes during  $\geq 30$ s, devices such as  
30  
31 pacemaker register atrial high rate and the benefit of apixaban is currently studied.<sup>28</sup>  
32  
33  
34 15 The correlation to symptoms is possible in our study and future smartphone-based  
35  
36 ICM usage is promising.<sup>29</sup>

37  
38  
39 Safety aspects during the study imply referral to the patients physician for  
40  
41 anticoagulation if AF is detected, sustained VT/ ventricular fibrillation for decision-  
42  
43 making with regard to an ICD and if a significant bradycardia occur that implies a  
44  
45  
46 20 pacemaker indication. If an ICD or pacemaker is indicated, the ICM will remain until  
47  
48 study end at 18 months.

49  
50  
51 Future research of larger series of HCM patients using ICMs with a larger sample  
52  
53 size allowing for analysis of subgroups like patients who have undergone myectomy  
54  
55 or alcohol septal ablation are welcomed. Interestingly, the ICM size has become  
56  
57  
58  
59  
60

1  
2  
3 reduced over time, and implantation techniques have become simpler, which allows  
4  
5 for more favourable cost-benefit as implantation outside the electrophysiological  
6  
7 laboratory is possible.  
8  
9

10 Still, this is the first study on arrhythmia burden and symptoms in consecutive  
11  
12 5 unselected HCM patients using an ICM connected to a smart-phone for monitoring  
13  
14 and symptom elucidation.  
15  
16

### 17 **Acknowledgements**

18  
19  
20 The authors acknowledge Anders Edström, Abbott, who provided support and  
21  
22 guidance.  
23  
24

### 25 10 **Author contributions**

26  
27  
28 PM: idea, design, project management, and writing the manuscript. SM: critical  
29  
30 revision of the manuscript and project management.  
31  
32

### 33 **Funding**

34  
35  
36 Region Gävleborg funded this research project and Abbott/St Jude Medical provided  
37  
38 15 funding for the Confirm Rx™ (grant number 84540).  
39  
40

### 41 **Competing interests**

42  
43  
44 The authors received a research grant from Abbott /St Jude Medical (see funding  
45  
46 section)  
47  
48

### 49 **Ethics approval**

50  
51  
52 20 The study was approved by the Regional Ethical committee in Umeå (Dnr 2017/13-  
53  
54 31).  
55  
56

### 57 **REFERENCES**

- 1  
2  
3 1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a  
4  
5 position statement from the European Society Of Cardiology Working Group on  
6  
7 Myocardial and Pericardial Diseases. *Eur Heart J* 2008; 29: 270-6.  
8  
9
- 10 2. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy  
11  
12 5 in a general population of young adults. Echocardiographic analysis of 4111 subjects  
13  
14 in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.  
15  
16 *Circulation* 1995;92:785-9.  
17  
18
- 19 3. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic  
20  
21 cardiomyopathy in China: a population-based echocardiographic analysis of 8080  
22  
23 10 adults. *Am J Med* 2004;116:14-18.  
24  
25  
26
- 27 4. Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of  
28  
29 hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2015;65:1249-54.  
30  
31
- 32 5. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left  
33  
34 ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations  
35  
36 15 and significance as assessed by two-dimensional echocardiography in 600 patients.  
37  
38 *J Am Coll Cardiol* 1995;26:1699-708.  
39  
40
- 41 6. Losi MA, Nistri S, Galderisi M, et al. Echocardiography in patients with  
42  
43 hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis  
44  
45 and pathophysiological assessment. *Cardiovasc Ultrasound* 2010;8:7.  
46  
47  
48
- 49 7. Magnusson P, Palm A, Branden E, et al. Misclassification of hypertrophic  
50  
51 cardiomyopathy: validation of diagnostic codes. *Clin Epidemiology* 2017;9: 403-10.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 8. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic Cardiomyopathy in Adulthood  
4 Associated With Low Cardiovascular Mortality With Contemporary Management  
5 Strategies. *J Am Coll Cardiol* 2015;65:1915-28.  
6  
7  
8  
9  
10 9. Maron BJ, Olivetto I, Spirito P, et al. Epidemiology of hypertrophic  
11  
12 5 cardiomyopathy-related death: revisited in a large non-referral-based patient  
13 population. *Circulation* 2000;102:858-64.  
14  
15  
16  
17 10. Pasqualucci D, Fornaro A, Castelli G, et al. Clinical Spectrum, Therapeutic  
18 Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy.  
19  
20  
21  
22  
23  
24 10 11. Guttman OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and  
25 thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.  
26  
27  
28  
29  
30  
31  
32 12. Magnusson P, Gadler F, Liv P, et al. Causes of death and mortality in  
33 hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden. *J*  
34  
35  
36 15 *Cardiovasc Med (Hagerstown)* 2016;17:478-84.  
37  
38  
39 13. Wang N, Xie A, Tjahjono R, et al. Implantable cardioverter defibrillator therapy in  
40 hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of  
41 outcomes and complications. *Annals of cardiothoracic surgery* 2017;6:298-306.  
42  
43  
44  
45  
46 14. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the  
47  
48  
49 20 diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a  
50 report of the American College of Cardiology Foundation/American Heart Association  
51 Task Force on Practice Guidelines. *Circulation* 2011;124:2761-96.  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 15. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis  
4 and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis  
5 and Management of Hypertrophic Cardiomyopathy of the European Society of  
6 Cardiology (ESC). *Eur Heart J* 2014;35:2733-79.  
7  
8  
9  
10  
11  
12 5 16. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia  
13 in hypertrophic cardiomyopathy: an independent marker of sudden death risk in  
14 young patients. *J Am Coll Cardiol*. 2003;42:873-9.  
15  
16  
17  
18  
19  
20 17. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic  
21 significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic  
22 cardiomyopathy. *J Am Coll Cardiol*. 2005;45:697-704.  
23  
24 10  
25  
26  
27 18. Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. Outcome and complications  
28 after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy:  
29 systematic review and meta-analysis. *Circ Heart Fail* 2012;5:552-9.  
30  
31  
32  
33  
34 19. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for  
35 sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). *Eur Heart J*  
36 15  
37 2014;35:2010-20.  
38  
39  
40  
41 20. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial  
42 fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;56:867-74.  
43  
44  
45  
46 21. Nölker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac  
47  
48  
49 20 Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. *J Cardiovasc*  
50  
51 *Electrophysiol* 2016;12:1403-10.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 22. Dubner S, Auricchio A, Steinberg J. et al. (2012). ISHNE/EHRA expert  
4 consensus on remote monitoring of cardiovascular implantable electronic devices  
5 (CIEDs). *Europace* 2012;14:278–93.  
6  
7  
8  
9  
10 23. (2002) World Medical Association Declaration of Helsinki: ethical principles for  
11  
12 5 medical research involving human subjects. *J Postgrad Med* 2002;48:206-8.  
13  
14  
15 24. European Medicines Agency (2002) ICH harmonised tripartite guideline E6. In:  
16  
17 EMA, eds. Note for Guidance on Good Clinical Practice (PMP/ICH/135/95).  
18  
19  
20 25. Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic  
21  
22 cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood  
23  
24 10 Institute. *Circulation* 2010;122:1130-3.  
25  
26  
27  
28 26. Sanna T, Diener HC, Passman RS, et al; CRYSTAL AF Investigators.  
29  
30 Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014;370:2478-86.  
31  
32  
33 27. Healey JS, Connolly SJ, Gold MR, et al.; ASSERT Investigators. Subclinical atrial  
34  
35 fibrillation and the risk of stroke. *N Engl J Med* 2012;366:120-9.  
36  
37  
38 15 28. NCT01938248. Apixaban for the Reduction of Thrombo-Embolism in Patients  
39  
40 with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA);  
41  
42 <https://clinicaltrials.gov/ct2/show/NCT01938248> (2 October 2017, date last  
43  
44 accessed).  
45  
46  
47 29. Mittal S. Smartphone-Based Electrocardiographic and Cardiac Implantable  
48  
49 20 Electronic Device Monitoring. *Cardiol Rev* 2017;25:12-16.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Evaluation Using Cardiac Insertable Devices And Telephone in Hypertrophic Cardiomyopathy (ELUCIDATE HCM) – rationale and design: a prospective observational study on incidence of arrhythmias in Sweden

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019541.R2
Article Type:	Protocol
Date Submitted by the Author:	30-Oct-2017
Complete List of Authors:	Magnusson, Peter; Center for Research and Development, Uppsala University/Region Gävleborg; Karolinska Institutet Mörner, Stellan; Umeå University, Department of Public Health and Clinical Medicine
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Adult cardiology < CARDIOLOGY, Cardiomyopathy < CARDIOLOGY, Heart failure < CARDIOLOGY, Pacing & electrophysiology < CARDIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic**  
4 **Cardiomyopathy (ELUCIDATE HCM) – rationale and design: a prospective**  
5 **observational study on incidence of arrhythmias in Sweden.**  
6  
7  
8

9  
10 Peter Magnusson<sup>1,2</sup> Stellan Mörner<sup>3</sup>

11  
12  
13 5 1. Cardiology Research Unit, Department of Medicine, Karolinska Institutet, Stockholm, SE-171 76,  
14 SWEDEN

15  
16 2. Centre for Research and Development, Uppsala University/Region Gävleborg, Gävle, SE-801 87,  
17 SWEDEN

18  
19 3. Department of Public Health and Clinical Medicine and Heart Center, Umeå University, Umeå, SE-  
20 90187, SWEDEN  
21  
22 10

23  
24  
25 **Correspondence to:**

26 Peter Magnusson

27 Cardiology Research Unit, Department of Medicine

28  
29  
30  
31 15 Karolinska Institutet

32 Karolinska University Hospital/Solna

33 SE-171 76 Stockholm, SWEDEN

34 Phone: +46(0)705 089407

35 Fax: +46(0)26 154255

36  
37  
38  
39  
40 20 E-mail: peter.magnusson@regiongavleborg.se  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50 25

## ABSTRACT

**Introduction:** Hypertrophic cardiomyopathy (HCM) is heterogeneous disease associated with sudden cardiac death (SCD) mainly due to ventricular tachycardia (VT) or fibrillation even though life threatening bradycardia occurs. Risk stratification takes several variables into consideration including non-sustained VT. An implantable cardioverter defibrillator effectively prevents SCD.

Atrial fibrillation (AF) is common among HCM patients and warrants anticoagulation even without conventional risk factors according to European guidelines. Routinely, the evaluation of arrhythmias using a 48 hour ambulatory external monitor takes place every 6 to 24 months if patients don't report palpitations. The remaining time the potential burden arrhythmia is unknown. Therefore, the aim of the present study is to assess NSVT and AF incidence during 18 months by an insertable cardiac monitor (ICM).

**Methods:** Adult patients, aged 18-65 years, with a validated diagnosis of HCM are eligible for the study. The study sample is planned to include 30 patients. A Confirm Rx™ is implanted at the level of the fourth rib on the left side subcutaneously after local anesthesia. The application for monitoring is installed in the patients smartphone and symptoms registered by the patient activation and VT detection programmed as 160bpm during  $\geq 8$  intervals. An AF episode is recorded based on  $\geq 2$  minutes duration. Bradycardia is recorded at  $\leq 40$ bpm or pause  $\geq 3.0$  seconds. The patients are followed during 18 months before explant.

**Ethics and dissemination:** The study was approved by The Regional Ethical Committee in Umeå (protocol number 2017/13-31) The study protocol, including

1  
2  
3 variables and pre-specified research questions the study was registered at Clinical  
4  
5 Trial Registration NCT03259113. Each patient is informed about the study in both  
6  
7 oral and written form by a physician and included after written consent.  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of this study

- An insertable cardiac monitor (ICM) allows for monitoring of atrial fibrillation, significant bradycardia, and non-sustained ventricular tachycardia during 18 months.
- The study will evaluate true incidence of arrhythmia including symptom registration using a smart-phone.
- Non-sustained ventricular tachycardia is a marker of sudden cardiac death but the decision to implant a defibrillator should be carefully evaluated using guidelines as an ICM is currently not an indication as a diagnostic tool in this regard.
- The costly and invasive ICM may need to be studied in larger hypertrophic cardiomyopathy cohorts to allow for subgroup analyses and to generalize findings.

**Keywords:** atrial fibrillation, hypertrophic cardiomyopathy, implantable loop recorder,

insertable cardiac monitor, non-sustained ventricular tachycardia

## INTRODUCTION

The hypertrophic cardiomyopathy (HCM) phenotype in adults requires at least 15mm thickness of the myocardial wall deemed unexplained by other myocardial diseases and abnormal loading conditions due to hypertension or aortic stenosis.<sup>1</sup> The point prevalence is approximately 1:500 in the general population but more than double if genotypes are also included.<sup>2-4</sup> Patients present with unspecific symptoms such as dyspnea, chest discomfort, palpitations, and dizziness. Echocardiogram is the cornerstone in diagnosing HCM but integrated medical information and awareness of differential diagnoses are important to avoid misclassification.<sup>5-7</sup> The severity and pattern of hypertrophy and disease progression varies considerably.<sup>5</sup> Life expectancy in general HCM cohorts seems to be acceptable but end-stage heart failure, cardiac embolization stroke, and devastating arrhythmias remain a challenge in order to improve prognosis.<sup>8-12</sup>

Sudden cardiac death (SCD) can be prevented by an implantable cardioverter-defibrillator (ICD). In a recent review of HCM patients with ICDs, 4.8% experienced appropriate therapy annually due to ventricular tachycardia (VT) or fibrillation and antitachycardia pacing or cardioversion rarely fails in terminating the arrhythmia.<sup>13</sup> The decision to implant an ICD as primary prevention of SCD is based on evaluation of riskmarkers according to guidelines.<sup>14,15</sup> In both 2011 and 2014 guidelines, non-sustained VT (NSVT) is part of risk stratification based on evidence from several studies.<sup>16-19</sup> It is more common at an older age and correlates with increased left ventricular wall thickness.<sup>16,20</sup> NSVT may be revealed during an ambulatory ECG, telemetry in the ward or during exercise test. HCM guidelines advocate follow-up including 48 hour ambulatory ECG whenever onset of palpitations or otherwise every 12-24 months but 6-12 months if the patient is in sinus rhythm and has enlarged left



atrial diameter which predisposes for atrial fibrillation (AF) and SCD.<sup>15</sup> This implies that during the remaining time the presence of NSVT/AF is unknown.

In HCM, AF is known to worsen symptoms due to vulnerability to increased heart rate and lack of atrial filling. Furthermore, AF associated with ischemic stroke or systemic embolization is a major cause of death in HCM, which warrants attention to detection methods with increased sensitivity.<sup>11</sup> In fact, according to current HCM-guidelines, a history of AF, even without any CHA2DS2-VASc risk factor is an indication of anticoagulation.<sup>15</sup>

The insertable cardiac monitor (ICM) Confirm Rx™ (Abbott/St. Jude Medical, St. Paul, MN, USA) provides long-term monitoring of atrial and ventricular arrhythmias in addition to bradycardia.<sup>21</sup> This device could potentially reveal the true incidence of arrhythmia in HCM patients which is the rationale of the present study: Evaluation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM).

## OBJECTIVES

Primary objective is to assess the incidence of NSVT during 18 months follow-up using an ICM.

Secondary objective is to assesses the incidence of AF during 18 months follow-up using an ICM.

## METHODS

### *Setting and selection*

Adult patients with a confirmed diagnosis of HCM, will be recruited from the catchment area of Region Gävleborg and Umeå University hospital (tertiary center) in

1  
2  
3 northern Sweden. Eligible patients are identified from hospital data-bases (diagnostic  
4 codes I42.1 or I42.2) and validated using medical records. The recruitment started in  
5 August 2017. The device will be implanted in addition to standard care.  
6  
7  
8

9  
10 *Inclusion and exclusion*  
11

12  
13 5 Patients, aged 18-65 years, with a confirmed diagnosis of HCM are eligible for the  
14 study. Exclusion criteria as follows: aortic stenosis (moderate, severe), hypertrophy  
15 associated with metabolic disease (e.g. Fabry-Andersen) and syndromes (e.g.  
16 Noonan syndrome), systolic heart failure with ejection fraction  $\leq 55\%$ , pacemaker,  
17 implantable defibrillator, myocardial infarction, percutaneous coronary intervention,  
18 coronary by-pass grafting, pulmonary vein isolation, Maze surgery, VT ablation,  
19 ectopic atrial tachycardia ablation, renal clearance  $\leq 40$  mL/min (Cockcroft-Gault  
20 Equation), malignancy or other comorbidity with  $\leq 5$  years life expectancy, pregnancy  
21 (or planned  $\leq 18$  months), drug addiction, severe psychiatric disease, not able to  
22 participate in 18 months follow-up, 5-year risk of sudden cardiac death  $\geq 6\%$   
23 according to the risk calculator.<sup>19</sup> Myectomy or alcohol septal ablation is not an  
24 exclusion criterion.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

40 *Implantation and monitor set-up*  
41

42  
43 The implantation procedure is performed in local infiltrative anesthesia (carbocaine  
44 with epinephrine) using the standard operation kit for Confirm Rx™ via a 5mm  
45 incision at the level of the fourth rib on the left side subcutaneously. The application for  
46 monitoring is installed on the patients own smart-phone or a one that will be lent  
47 during the study period. The connection to the home-monitoring site Merlin™ is  
48 administrated and the patient is instructed how to use application and report potential  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 symptoms according to guidelines.<sup>22</sup> Post-procedure, paracetamol (acetaminophen)  
4  
5 is recommended to control pain.  
6  
7

### 8 *Programming*

9  
10 VT detection is programmed as 160bpm during  $\geq 8$  intervals with high electrogram  
11  
12 (EGM) priority and discriminator sudden onset activated (onset delta 18%) a  
13 5  
14 bigemini qualifier off. An AF episode is recorded based on  $\geq 2$  minutes duration (the  
15  
16 shortest programmable duration), AF-burden  $\geq 6$  hours a day, or ventricular rate  
17  
18 during AF 100bpm for 6 hours daily. Bradycardia is recorded at  $\leq 40$ bpm or pause  
19  
20  $\geq 3.0$  seconds. Patient-activated symptom episodes have high EGM priority with 6  
21  
22 10 minutes symptom pre-trigger duration and 1 minute symptom post-trigger duration  
23  
24 and the first 8 EGMs are stored. Maximal ventricular sensitivity is typically 0.15mV  
25  
26 but adjusted if R-waves are low. Threshold start is 75% and sense refractory period  
27  
28 250ms and decay delay 60ms.  
29  
30  
31  
32

### 33 *Follow-up*

34  
35  
36 15 Patients are encouraged to report symptoms by using the smart phone application. In  
37  
38 addition, every third month there is an automatic interrogation of the device and  
39  
40 transfer to the home-monitoring site Merlin,<sup>TM</sup> which is reviewed every second day  
41  
42 except for weekends. False detection of arrhythmia by the device is expected to be  
43  
44 frequent based on experience. Therefore all episodes are scrutinized as part of work-  
45  
46 20 process. At 18 months, the device is explanted. Patients are scheduled for follow-up  
47  
48 every third months but detection of arrhythmia warrants contact with the patient as  
49  
50 part of clinical management.  
51  
52  
53  
54

### 55 *Power analysis*

1  
2  
3 A power analysis is based on previous research findings and estimation of outcome  
4 with certain relevance of hypothesis testing. This is the first study on incidence of  
5 NSVT and AF in HCM using continuous monitoring for a period of 18 months. Thus  
6 the diagnostic yield is unknown. A formal power analysis is have not been conducted  
7  
8  
9  
10  
11  
12 5 and estimation of sample size is based on clinical judgement and available  
13  
14 resources.

### 15 16 17 *Statistics*

18  
19  
20 Numeric data will be presented as frequencies, percentages, means, and percentiles.  
21  
22 Continuous variables are summarized as means, standard deviations, and  
23  
24 10 percentiles, and compared using t-tests. The chi-squared test is used for categorical  
25  
26 variables. Kaplan-Meier estimates is used to describe time to event analysis (time  
27  
28 from implant to AF and NSVT respectively and cumulative incidence at 6,12, and 18  
29  
30 months will be reported.  
31

32  
33  
34 A two-sided  $p$ -value of  $<0.05$  is considered statistically significant. The database will  
35  
36 15 be stored in Excel 2010 (Microsoft Corporation, Redmond, WA) and imported into  
37  
38 SPSS version 22 (IBM, Armonk, NY) for statistical analyses.  
39

### 40 41 *Variables*

42  
43  
44 Patient characteristics at enrollment as follows: age, family history of SCD,  
45  
46 unexplained syncope, known HCM associated mutation, weight, length, NSVT at 48  
47  
48 20 hours ECG. Echocardiography parameters such as maximal wall thickness, left  
49  
50 ventricular outflow tract gradient, left atrial size will be recorded.  
51

### 52 53 *Ethics and dissemination*

1  
2  
3 The Regional Ethical Committee in Umeå approved the study the 7<sup>th</sup> of February  
4  
5 2017 (protocol number 2017/13-31), which is conducted in accordance with the  
6  
7 Declaration of Helsinki.<sup>23</sup> The study protocol, including variables and pre-specified  
8  
9 research questions the study was registered at Clinical Trial Registration  
10  
11 NCT03259113 and approved 24<sup>th</sup> of August 2017. Documentaton of research data  
12  
13 and management of study follow Guideline for Good Clinical Practice.<sup>24</sup> Each patient  
14  
15 is informed about the study in both oral and written form by a physician and included  
16  
17 after written consent. After the follow-up period is completed, the database will be  
18  
19 close and followed by statistical work, interpretation of results, and dissemination to a  
20  
21 scientific journal.  
22  
23  
24  
25

## 26 **DISCUSSION**

27  
28 This is the first study on arrhythmia detection in HCM using an ICM. These devices  
29  
30 offer the superior advantage of prolonged monitoring in comparison to external loop-  
31  
32 recorders. ICM is currently used in certain cases of HCM such as syncope evaluation  
33  
34 or possibly in patients with frequent palpitations, but not in routine evaluation. The  
35  
36 application of ICM in the specific group of HCM has been proposed already in  
37  
38 statements of research priorities.<sup>25</sup>  
39  
40  
41

42 The newly launched Confirm Rx<sup>TM</sup> uses a smart-phone application that is used  
43  
44 instead of a standard home-monitor and provide the possibility of remote monitoring  
45  
46 and symptom registration.  
47  
48  
49

50 Until now, 48 hour ambulatory monitoring is used, but often telemetry in hospital  
51  
52 wards detect arrhythmias in HCM. That means that these modes of monitoring may  
53  
54 coincidentally detect AF and VT but with increased likelihood in patients with higher  
55  
56 incidence of arrhythmias. It is unclear if a higher incidence of arrhythmia reflects a  
57  
58  
59  
60

1  
2  
3 higher risk of SCD/stroke and our study has a small sample size and no long-term  
4  
5 follow-up of outcomes of SCD. Even though this study will elucidate the true  
6  
7 arrhythmia incidence, the clinical interpretation will remain partly unsolved. In  
8  
9 addition, ICMs are costly devices and health economy analyses will be needed  
10  
11  
12 5 before potential use in broader HCM groups.

13  
14 Detection of AF is important in HCM because of the increased of embolic stroke.<sup>11</sup>  
15  
16 AF detection by ICM is superior compared to standard evaluation of monitoring in  
17  
18 cryptogenic stroke.<sup>26</sup> However, it should be remembered that clinical management of  
19  
20 patients whose AF was detected at pacemaker interrogation is controversial, but  
21  
22  
23 10 there is compelling evidence when duration is at least six minutes.<sup>27</sup> Patients with  
24  
25 silent AF, i.e. asymptomatic still carry a considerable risk and should be managed the  
26  
27 conventional way with regard to anticoagulation.<sup>27</sup> Even though the definition of AF is  
28  
29 an atrial electrical activity of  $\geq 300$  beats per minutes during  $\geq 30$ s, devices such as  
30  
31 pacemaker register atrial high rate and the benefit of apixaban is currently studied.<sup>28</sup>  
32  
33  
34 15 The correlation to symptoms is possible in our study and future smartphone-based  
35  
36 ICM usage is promising.<sup>29</sup>

37  
38  
39 Safety aspects during the study imply referral to the patients physician for  
40  
41 anticoagulation if AF is detected, sustained VT/ ventricular fibrillation for decision-  
42  
43 making with regard to an ICD and if a significant bradycardia occur that implies a  
44  
45  
46 20 pacemaker indication. If an ICD or pacemaker is indicated, the ICM will remain until  
47  
48 study end at 18 months.

49  
50  
51 Future research of larger series of HCM patients using ICMs with a larger sample  
52  
53 size allowing for analysis of subgroups like patients who have undergone myectomy  
54  
55 or alcohol septal ablation are welcomed. Interestingly, the ICM size has become  
56  
57  
58  
59  
60

1  
2  
3 reduced over time, and implantation techniques have become simpler, which allows  
4  
5 for more favourable cost-benefit as implantation outside the electrophysiological  
6  
7 laboratory is possible.  
8  
9

10 Still, this is the first study on arrhythmia burden and symptoms in consecutive  
11  
12 5 unselected HCM patients using an ICM connected to a smart-phone for monitoring  
13  
14 and symptom elucidation.  
15  
16

### 17 **Acknowledgements**

18  
19  
20 The authors acknowledge Anders Edström, Abbott, who provided support and  
21  
22 guidance.  
23  
24

### 25 10 **Author contributions**

26  
27  
28 PM: idea, design, project management, and writing the manuscript. SM: critical  
29  
30 revision of the manuscript and project management.  
31  
32

### 33 **Funding**

34  
35  
36 Region Gävleborg funded this research project and Abbott/St Jude Medical provided  
37  
38 15 funding for the Confirm Rx™ (grant number 84540).  
39  
40

### 41 **Competing interests**

42  
43  
44 The authors received a research grant from Abbott /St Jude Medical (see funding  
45  
46 section)  
47  
48

### 49 **Ethics approval**

50  
51  
52 20 The study was approved by the Regional Ethical committee in Umeå (Dnr 2017/13-  
53  
54 31).  
55  
56

### 57 **REFERENCES**

- 1  
2  
3 1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a  
4  
5 position statement from the European Society Of Cardiology Working Group on  
6  
7 Myocardial and Pericardial Diseases. *Eur Heart J* 2008; 29: 270-6.  
8  
9
- 10 2. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy  
11  
12 5 in a general population of young adults. Echocardiographic analysis of 4111 subjects  
13  
14 in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.  
15  
16 *Circulation* 1995;92:785-9.  
17  
18
- 19 3. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic  
20  
21 cardiomyopathy in China: a population-based echocardiographic analysis of 8080  
22  
23 10 adults. *Am J Med* 2004;116:14-18.  
24  
25  
26
- 27 4. Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of  
28  
29 hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2015;65:1249-54.  
30  
31
- 32 5. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left  
33  
34 ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations  
35  
36 15 and significance as assessed by two-dimensional echocardiography in 600 patients.  
37  
38 *J Am Coll Cardiol* 1995;26:1699-708.  
39  
40
- 41 6. Losi MA, Nistri S, Galderisi M, et al. Echocardiography in patients with  
42  
43 hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis  
44  
45 and pathophysiological assessment. *Cardiovasc Ultrasound* 2010;8:7.  
46  
47  
48
- 49 20 7. Magnusson P, Palm A, Branden E, et al. Misclassification of hypertrophic  
50  
51 cardiomyopathy: validation of diagnostic codes. *Clin Epidemiology* 2017;9: 403-10.  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 8. Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic Cardiomyopathy in Adulthood  
4 Associated With Low Cardiovascular Mortality With Contemporary Management  
5 Strategies. *J Am Coll Cardiol* 2015;65:1915-28.  
6  
7  
8  
9  
10 9. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic  
11  
12 5 cardiomyopathy-related death: revisited in a large non-referral-based patient  
13 population. *Circulation* 2000;102:858-64.  
14  
15  
16  
17 10. Pasqualucci D, Fornaro A, Castelli G, et al. Clinical Spectrum, Therapeutic  
18 Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy.  
19  
20  
21  
22  
23  
24 10 11. Guttman OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and  
25  
26 thromboembolism in patients with hypertrophic cardiomyopathy: systematic review.  
27  
28  
29  
30  
31  
32 12. Magnusson P, Gadler F, Liv P, et al. Causes of death and mortality in  
33  
34 hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden. *J*  
35  
36 15 *Cardiovasc Med (Hagerstown)* 2016;17:478-84.  
37  
38  
39 13. Wang N, Xie A, Tjahjono R, et al. Implantable cardioverter defibrillator therapy in  
40  
41 hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of  
42  
43 outcomes and complications. *Annals of cardiothoracic surgery* 2017;6:298-306.  
44  
45  
46 14. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the  
47  
48 20 diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a  
49  
50 report of the American College of Cardiology Foundation/American Heart Association  
51  
52 Task Force on Practice Guidelines. *Circulation* 2011;124:2761-96.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 15. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis  
4 and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis  
5 and Management of Hypertrophic Cardiomyopathy of the European Society of  
6 Cardiology (ESC). *Eur Heart J* 2014;35:2733-79.  
7  
8  
9  
10  
11  
12 5 16. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia  
13 in hypertrophic cardiomyopathy: an independent marker of sudden death risk in  
14 young patients. *J Am Coll Cardiol*. 2003;42:873-9.  
15  
16  
17  
18  
19  
20 17. Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic  
21 significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic  
22 cardiomyopathy. *J Am Coll Cardiol*. 2005;45:697-704.  
23  
24 10  
25  
26  
27 18. Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. Outcome and complications  
28 after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy:  
29 systematic review and meta-analysis. *Circ Heart Fail* 2012;5:552-9.  
30  
31  
32  
33  
34 19. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for  
35 sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). *Eur Heart J*  
36 15  
37 2014;35:2010-20.  
38  
39  
40  
41 20. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial  
42 fibrosis in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2010;56:867-74.  
43  
44  
45  
46 21. Nölker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac  
47  
48  
49 20 Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. *J Cardiovasc*  
50  
51 *Electrophysiol* 2016;12:1403-10.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 22. Dubner S, Auricchio A, Steinberg J. et al. (2012). ISHNE/EHRA expert  
4 consensus on remote monitoring of cardiovascular implantable electronic devices  
5 (CIEDs). *Europace* 2012;14:278–93.  
6  
7  
8  
9  
10 23. (2002) World Medical Association Declaration of Helsinki: ethical principles for  
11  
12 5 medical research involving human subjects. *J Postgrad Med* 2002;48:206-8.  
13  
14  
15 24. European Medicines Agency (2002) ICH harmonised tripartite guideline E6. In:  
16  
17 EMA, eds. Note for Guidance on Good Clinical Practice (PMP/ICH/135/95).  
18  
19  
20 25. Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic  
21  
22 cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood  
23  
24 10 Institute. *Circulation* 2010;122:1130-3.  
25  
26  
27  
28 26. Sanna T, Diener HC, Passman RS, et al; CRYSTAL AF Investigators.  
29  
30 Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014;370:2478-86.  
31  
32  
33 27. Healey JS, Connolly SJ, Gold MR, et al.; ASSERT Investigators. Subclinical atrial  
34  
35 fibrillation and the risk of stroke. *N Engl J Med* 2012;366:120-9.  
36  
37  
38 15 28. NCT01938248. Apixaban for the Reduction of Thrombo-Embolism in Patients  
39  
40 with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA);  
41  
42 <https://clinicaltrials.gov/ct2/show/NCT01938248> (2 October 2017, date last  
43  
44 accessed).  
45  
46  
47 29. Mittal S. Smartphone-Based Electrocardiographic and Cardiac Implantable  
48  
49 20 Electronic Device Monitoring. *Cardiol Rev* 2017;25:12-16.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60